Printer Friendly

Avigen obtains United States patent.

Avigen, Inc. (Alameda, CA) has patented a method for using recombinant adeno-associated virus virions for delivery of DNA molecules to muscle cells and tissue. The invention allows for the direct, in vivo injection of recombinant adeno-associated virus virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of the delivered gene and for in vivo secretion of the therapeutic protein from transduced muscle cells such that systemic delivery is achieved. (US 6,391,858)
COPYRIGHT 2002 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Avigen obtains United States patent.(Brief Article)
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:May 1, 2002
Previous Article:Oregon Health & Science University obtains United States patent.
Next Article:Chiron obtains United States patent.

Related Articles
Avigen further expands its extensive adeno-associated viral patent portfolio.
Avigen licenses adeno-associated virus vector technology to Stratagene.
du Pont obtains United States patent.
ARCH obtains United States patent.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |